{"prompt": "['Novartis', 'Confidential', 'Page 14', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'The changes described in this amended protocol require IRB/IEC approval prior to', 'implementation.', 'The changes herein affect the Informed Consent. Sites are required to update and submit for', 'approval, a revised Informed Consent that takes into account the changes described in this', 'protocol amendment.', 'Amendment 1', 'Amendment rationale', 'The protocol is being amended based on health authority feedback - the following changes have', 'been implemented:', 'Added additional exclusion criteria to Section 5.2 to ensure that patients taking any of the', 'prohibited medications outlined in Table 6-2 are appropriately excluded.', 'Changes to the protocol', 'The described changes in the aforementioned amendment rationale are implemented throughout', 'the protocol in the sections noted.', 'The opportunity was also taken to amend typographical items in the protocol:', 'Rewording of the text for the restriction on nasal corticosteroids in Table 6-2 to better', 'clarify the specific types that are excluded along with the restricted statin therapies', 'Minor revision to the wording in Section 8.3.3']['Novartis', 'Confidential', 'Page 15', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Protocol summary', 'Protocol number', 'CQAW039A2322', 'Full Title', 'A multicenter, randomized, double-blind, parallel-group, placebo-controlled', 'study of fevipiprant once daily plus standard-of-care (SoC) for assessment of', 'the efficacy in reduction of nasal polyp size in patients with nasal polyposis and', 'concomitant asthma.', 'Brief title', 'Study of efficacy of fevipiprant in patients with nasal polyposis and asthma', 'Sponsor and', 'Novartis', 'Clinical Phase', 'Phase 3b', 'Investigation', 'Drug', 'type', 'Study type', 'Interventional', 'Purpose and', 'Nasal polyposis is a common disorder, affecting up to 4% of the population.', 'rationale', 'Although the causes remain unclear, nasal polyposis has been associated with', 'a number of conditions including, asthma, infection, cystic fibrosis and aspirin', 'sensitivity. Nasal polyposis with concomitant asthma has a prevalence ranging', 'from 2%-66% although it is usually in the region of 30% of those nasal', 'polyposis patients who are referred to (ear, nose, throat) ENT departments.', 'The purpose of this study is to evaluate the efficacy and safety of fevipiprant 150', 'mg and 450 mg compared to placebo in the reduction of nasal polyps size and', 'the effect on symptoms, quality of life and smell via patient-reported outcomes', 'in patients with nasal polyposis (NP) and concomitant asthma.', 'Primary', 'In patients with nasal polyps with a polyp size score 4 at baseline, to', 'Objective(s)', 'demonstrate a difference in mean change from baseline in polyp size at', 'Week 16, measured by the nasal polyp score (NPS, assessed by nasal', 'endoscopy with central reading), between fevipiprant (150 mg or 450 mg', 'once daily, separately) and placebo', 'Secondary', 'To evaluate the effect on symptoms as measured by the nasal congestion', 'Objectives', 'score (NCS) with fevipiprant (150 mg or 450 mg once daily), compared', 'with placebo following 16 weeks of treatment.', 'To evaluate the effect on quality of life as measured by the Sino-Nasal', 'Outcome Test - 22 (SNOT-22) with fevipiprant (150 mg or 450 mg once', 'daily), compared with placebo following 16 weeks of treatment.', 'To evaluate the effect on Smell as measured by the university of', 'Pennsylvania smell identification test (UPSIT) with fevipiprant (150 mg or', '450 mg once daily), compared with placebo following 16 weeks of', 'treatment.', 'To evaluate the effect of fevipiprant 150 mg and 450 mg compared with', 'placebo in terms of general safety/tolerability following 16 weeks of', 'treatment.', 'Study design', 'This is a Phase 3b, Proof-of-concept study with a randomized, multicenter,', 'double-blind, placebo-controlled, parallel-group study design to determine the', 'ability of fevipiprant plus SoC compared to placebo plus SoC to reduce the size', 'of NPs. The study will include: Screening period of 2 weeks to assess eligibility;', 'Run-in period of 4 weeks where patients will utilize mometasone furoate spray', '(200 g once daily, administered as two 50 g actuations into each nostril);', 'Treatment period of 16 weeks (with visits held every month for study', 'procedures) and a Follow-up period of 2 weeks following the last dose of study']['Novartis', 'Confidential', 'Page 16', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'drug to collect additional data for safety variables. Patients will continue to use', 'the mometasone furoate SoC throughout the treatment period.', 'Population', 'The study population will consist of approximately 93 male and female patients', 'aged 18 and above, diagnosed with nasal polyposis with nasal polyp size score', '4 (nasal polyp score, assessed by nasal endoscopy) with a minimum score of', '2 in each nostril; and a concomitant diagnosis of asthma.', 'Key Inclusion', 'Written informed consent must be obtained before any assessment is', 'criteria', 'performed.', 'Patients aged 18 years with a diagnosis of nasal polyposis with nasal', 'polyp size score 4 and a minimum score of 2 in each nostril, measured', 'by nasal endoscopy at screening and prior to randomization on Run-', 'in/Treatment Day 1 (to ensure no reduction in NPS following the use of the', 'mometasone furoate SoC therapy).', 'Patients with a concomitant diagnosis of asthma for a period of at least 6', 'months prior to screening.', 'Have been on a stable asthma treatment regimen of at least inhaled', 'corticosteroids (ICS, any dose), alone for at least 6 months prior to', 'Screening or ICS for 6 months prior to Screening with any other required', 'inhaled asthma medication (long-acting bronchodilator (LABA), long-acting', 'muscarinic antagonist (LAMA)) added at least 6 weeks prior to Screening.', 'Key Exclusion', 'Asthma exacerbation, within 6 weeks prior to Screening that required', 'criteria', 'systemic corticosteroids, hospitalization, or emergency room visit. When', 'patients experience an exacerbation between screening and the end of the', '4', 'week Run-in period, and prior to randomization, they will be considered', 'screen failures and can be eligible for re-screening only once the required', '6 weeks post-exacerbation window has passed.', 'Chronic/maintenance use of oral corticosteroids (OCS) defined as any', 'continuous use of OCS for a period of 1 month or more within 1 year of', 'Screening.', 'Use of biologics (omalizumab, mepolizumab, reslisumab, dupilumab,', 'benralizumab etc., for asthma or any other indications) that has potential to', 'interfere/affect asthma or NP disease progression, within 6 months of the', 'start of the Run-in period.', 'Use of medication for sino-nasal symptoms (antibiotics with or without', 'OCS) within 30 days of Screening or during the Run-in period.', 'Any contra-indications to inhaled or nasal steroids e.g. narrow angle', 'glaucoma, or any other as decided by the Investigator.', 'History of nasal surgery (including polypectomy) within 6 months prior to', 'screening.', 'Patients with asthma control questionnaire - 5 questions (ACQ-5) 1.5 at', 'Screening', 'Study treatment', 'QAW039 150 mg and QAW039 450 mg once daily', 'Matching placebo to QAW039 150 mg and QAW039 450 mg once daily', 'Efficacy', 'Assessment of nasal polyp score by nasal endoscopy', 'assessments', 'Assessment of nasal congestion using the nasal congestion score', 'questionnaire', 'Assessment of quality of life using the SNOT-22 questionnaire', 'Assessment of smell using the university of Pennsylvania smell', 'identification test']\n\n###\n\n", "completion": "END"}